Compared with the control groups, the nude mice bearing DAGLA-knockdown tumours and receiving lenvatinib treatment showed better tumour growth inhibition, while nude mice bearing DAGLA-overexpressing tumours exhibited significant lenvatinib resistance, which could be strongly reversed by the combined treatment of verteporfin and lenvatinib (Fig. 7F–I). The gene discussed is DAGLA; the disease is neoplasm.